# SetPoint Medical Corporation Startup profile on Capital Atlas: https://capitalatlas.ai/startups/setpoint-medical - Industry: Biotechnology - Headquarters: Valencia, US - Website: www.setpointmedical.com - Total disclosed funding: $321M - Latest round: Series D (Mar 27, 2025) - Investors on record: 25 ## About SetPoint Medical Corporation, based in the US, develops innovative treatment solutions utilizing proprietary Neuroimmune Modulation technology aimed at regulating inflammation and restoring immunologic balance for chronic autoimmune diseases. SetPoint Medical Corporation specializes in advanced treatment solutions through its investigational medical device platform. Founded in 2007 and headquartered in Valencia, US, the company has successfully raised USD 115.00 mn in Series D funding as part of its growth strategy, bringing the total amount raised to USD 115.00 mn. The CEO is Murthy Simhambhatla, who leads the company in its clinical research efforts and strategic partnerships. SetPoint has conducted a total of 15 deals, with the most recent deal occurring on March 27, 2025.SetPoint Medical focuses on innovating treatment solutions through its proprietary platform, Neuroimmune Modulation, which employs targeted electrical stimulation to activate the body's immunomodulatory pathways. This technology aims to regulate inflammation and restore immunologic balance, primarily addressing chronic autoimmune diseases. The company’s core product offering is an investigational medical device intended for clinical use, aiming to enhance patient outcomes by providing a novel therapeutic approach. The technology targets patients suffering from chronic autoimmune conditions, particularly in the United States and global markets involved in clinical trials, and is supported by extensive clinical research to refine and expand its customer base among healthcare providers. SetPoint Medical generates revenue through its investigational medical device platform, focusing on clinical trials and partnerships with healthcare institutions. Collaborations with medical facilities and research organizations are integral for evaluating the efficacy of its Neuroimmune Modulation technology. While specific pricing details for its offerings have not been disclosed, revenue is primarily derived from partnerships, research grants, and potential future sales to healthcare providers following regulatory approval. The financial framework will evolve as the company progresses through clinical research and regulatory processes. In March 2025, SetPoint Medical Corporation raised USD 115 million in Series D funding to support its future growth strategies. The company plans to enhance its product offerings and expand its market reach, targeting new geographic regions for its investigational devices. The recent funding will bolster research and development efforts, facilitating the introduction of new products designed to improve treatment for chronic autoimmune diseases. SetPoint aims to solidify its presence in both existing and new markets as it advances its clinical trials and navigates regulatory pathways. ## Funding rounds - Series D, Mar 27, 2025, $115M — Ally Bridge Group, Elevage Medical Technologies, LP - Series C, Jan 18, 2023, $55M — Morgenthaler Ventures, New Enterprise Associates, Norwest Venture Partners, Richard King Mellon Foundation, Topspin Partners, Viking Global Investors, Boston Scientific Ventures, Action Potential Venture Capital, Midas Capital, Euclidean Capital, ShangBay Capital, SVE Capital, Catalio Capital Management, Ascendum Capital, Citta Capital, Gilmartin Capital - Series B, Jan 27, 2021, $12M — Morgenthaler Ventures, New Enterprise Associates, Richard King Mellon Foundation, Topspin Partners, Boston Scientific Ventures, Action Potential Venture Capital, Revelation Partners, Midas Capital, Euclidean Capital, ShangBay Capital, SVE Capital, Aethan Capital, Inc., Asahi Kasei Corporate Venture Capital, Catalio Capital Management, Ascendum Capital, Citta Capital, Banyan Pacific Capital - Series B, Oct 30, 2020, $52M — Morgenthaler Ventures, New Enterprise Associates, Richard King Mellon Foundation, Topspin Partners, Boston Scientific Ventures, Action Potential Venture Capital, Revelation Partners, Midas Capital, Euclidean Capital, ShangBay Capital, SVE Capital, Aethan Capital, Inc., Asahi Kasei Corporate Venture Capital, Catalio Capital Management, Ascendum Capital, Citta Capital, Banyan Pacific Capital - Series D, Aug 28, 2017, $30M — Morgenthaler Ventures, New Enterprise Associates, Topspin Partners, Medtronic, Boston Scientific Ventures, Action Potential Venture Capital - Series C, Aug 21, 2015, $15M — Morgenthaler Ventures, Foundation Medical Partners, Topspin Partners, Boston Scientific Ventures, Medtronic Ventures, Action Potential Venture Capital - Series C, Aug 8, 2013, $31M — Morgenthaler Ventures, Foundation Medical Partners, Topspin Partners, Boston Scientific Ventures, Medtronic Ventures, Action Potential Venture Capital - Series B, Oct 13, 2010, $5M — Foundation Medical Partners - Series A, May 17, 2007, $6M — Morgenthaler Ventures, Foundation Medical Partners ## Investors - Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series C, Series D, Series B - Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series A, Series B, Series C - Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series C, Series D, Series B - Boston Scientific Ventures (https://capitalatlas.ai/funds/boston-scientific-ventures) — Series C, Series D, Series B - Medtronic Ventures (https://capitalatlas.ai/funds/medtronic-ventures) — Series C - Action Potential Venture Capital (https://capitalatlas.ai/funds/action-potential-venture-capital) — Series C, Series D, Series B - New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series D, Series B, Series C - Medtronic — Series D - Richard King Mellon Foundation — Series B, Series C - Revelation Partners (https://capitalatlas.ai/funds/revelation-partners) — Series B - Midas Capital — Series B, Series C - Euclidean Capital — Series B, Series C - ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series B, Series C - SVE Capital (https://capitalatlas.ai/funds/sve-capital) — Series B, Series C - Aethan Capital, Inc. — Series B - Asahi Kasei Corporate Venture Capital — Series B - Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B, Series C - Ascendum Capital (https://capitalatlas.ai/funds/ascendum-capital) — Series B, Series C - Citta Capital — Series B, Series C - Banyan Pacific Capital — Series B - Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series C - Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series C - Gilmartin Capital (https://capitalatlas.ai/funds/gilmartin-capital) — Series C - Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D - Elevage Medical Technologies, LP — Series D